Literature DB >> 7420439

Chronic airways obstruction in pulmonary sarcoidosis: its poor response to bronchodilators.

R C Young, G K Sahetya, S N Hassan, W B Cobb, B Kumar, H T Facen.   

Abstract

Emphysema, chronic bronchitis, asthma, and cystic fibrosis are often cited as examples of chronic airways obstruction, while sarcoidosis is typically restrictive. Approximately 15 percent of sarcoidosis patients, however, have airways obstruction clinically characterized by wheezing with granulomatous involvement of airways. Since the majority have Stage IV disease by chest radiograph, their lungs usually have honey-combining with pulmonary fibrosis, adhesions, cavities, and mediastinal distortion.Patients had a mixed ventilatory defect, but obstruction of large airways was present as shown by decreased specific airways conductances. Small airways obstruction was also present as shown by low instantaneous flows at the terminal portion of the maximum expiratory flow-volume curve and diminished helium response of this curve. The closing volume, however, was not very sensitive. Radioactive xenon washout from ventilation lung scans and N2 washout from the lungs were prolonged in patients with worse disease.The authors conclude that the obstructive type of physiologic pattern is more frequent than recognized in sarcoidosis, which like that of cystic fibrosis has some restrictive element and is characterized by poor reversibility to bronchodilators. A trial period of beclomethasone dipropionate aerosol was not helpful in two patients. Relief of this distressing airways obstruction continues to pose a challenging problem in management.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7420439      PMCID: PMC2552536     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  13 in total

1.  Pulmonary function in sarcoidosis; results with cortisone therapy.

Authors:  D J STONE; A SCHWARTZ; J A FELTMAN; F J LOVELOCK
Journal:  Am J Med       Date:  1953-10       Impact factor: 4.965

2.  Pulmonary function studies in sarcoidosis.

Authors:  E O COATES; J H COMROE
Journal:  J Clin Invest       Date:  1951-08       Impact factor: 14.808

3.  Sarcoidosis: a correlation of dyspnea with roentgenographic stage and pulmonary function changes.

Authors:  R A DeRemee; H A Andersen
Journal:  Mayo Clin Proc       Date:  1974-10       Impact factor: 7.616

4.  Pulmonary function in a case of endobronchial sarcoidosis.

Authors:  S R Benatar; T J Clark
Journal:  Am Rev Respir Dis       Date:  1974-10

5.  Alpha 1 antitrypsin levels in sarcoidosis: relationship to disease activity.

Authors:  R C Young; V E Headings; S Bose; K A Harden; E D Crockett; R L Hackney
Journal:  Chest       Date:  1973-07       Impact factor: 9.410

6.  Pulmonary function in diffuse sarcoidosis.

Authors:  G Renzi; R E Dutton
Journal:  Respiration       Date:  1974       Impact factor: 3.580

7.  Airway function in chronic pulmonary sarcoidosis with fibrosis.

Authors:  A Miller; A S Teirstein; I Jackler; M Chuang; L E Siltzbach
Journal:  Am Rev Respir Dis       Date:  1974-02

8.  Airway obstruction in pulmonary sarcoidosis.

Authors:  K Kaneko; O P Sharma
Journal:  Bull Eur Physiopathol Respir       Date:  1977 Mar-Apr

9.  The Use of a Helium-Oxygen Mixture during Maximum Expiratory Flow to Demonstrate Obstruction in Small Airways in Smokers.

Authors:  J Dosman; F Bode; J Urbanetti; R Martin; P T Macklem
Journal:  J Clin Invest       Date:  1975-05       Impact factor: 14.808

10.  Airway function in sarcoidosis.

Authors:  R S Levinson; L F Metzger; N N Stanley; S G Kelsen; M D Altose; N S Cherniack; J S Brody
Journal:  Am J Med       Date:  1977-01       Impact factor: 4.965

View more
  4 in total

1.  Are sociodemographic factors important in sarcoidosis?

Authors:  R C Young
Journal:  J Natl Med Assoc       Date:  1999-06       Impact factor: 1.798

2.  Primary care paradigm for management of sarcoidosis, Part 2.

Authors:  R C Young; R E Rachal; B Nelson-Knuckles; C N Arthur; H V Nevels
Journal:  J Natl Med Assoc       Date:  1997-04       Impact factor: 1.798

3.  Clinical and polysomnographic evaluation of sleep-related breathing disorders in patients with sarcoidosis.

Authors:  Özlem Ataoğlu; Ali Nihat Annakkaya; Peri Meram Arbak; Pınar Yildiz Gülhan; Mehmet Fatih Elverişli
Journal:  Sleep Breath       Date:  2022-01-31       Impact factor: 2.816

4.  When should sarcoidosis be treated?

Authors:  R C Young; R E Rachal; C L Cowan
Journal:  J Natl Med Assoc       Date:  1986-09       Impact factor: 1.798

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.